ODM Clinic study (Phase1 - Phase 4） Manufacturer, Suppliers
Request Study Details
From initial active constituent isolation to global multi-center trials, our dedicated contract pipelines deliver standardized botanical dossiers designed for regulatory defense.
The botanical drug and dietary supplement industry is undergoing an unprecedented transition from experiential empiricism to quantitative molecular verification.
Traditional herbal ingredient suppliers face collapsing margins due to reliance on unstandardized crude powders and basic ratio extracts (e.g., 4:1, 10:1). Global pharmaceutical buyers and top-tier nutraceutical brands now demand rigorous chemical characterization and clear mechanisms of action (MoA).
International agencies such as the US FDA (Botanical Drug Development Guidance), EMA (HMPC monographs), and NMPA have established rigorous thresholds for batch uniformity, stability, and chromatographic fingerprint consistency across multiple harvest seasons.
Contract Research Organizations (CROs) specialized in natural medicine eliminate the risk of exploratory internal R&D. By acting as an ODM partner, Yineng Pharma bridges upstream agronomic discovery directly into validated downstream commercial formulation.
Our validated ODM research framework guarantees complete data integrity, reproducibility, and rigorous chromatographic alignment at every operational milestone.
Utilizing high-performance thin-layer chromatography (HPTLC) and metabolomic profiling to evaluate bioactive density across diverse harvesting seasons, geographical microclimates, and plant anatomical fractions (roots, aerial parts, seeds).
Developing calibrated HPLC, GC-MS, and LC-MS/MS analytical methodologies. Establishing characteristic reference fingerprints to differentiate authentic active species from potential adulterants and quantifying primary and secondary marker compounds.
Executing targeted cellular models (receptor binding, inflammatory cytokine suppression, antioxidant enzyme modulation) followed by rodent in vivo models to assess systemic biodistribution, acute toxicity (LD50), and repeated-dose sub-chronic tolerability.
Conducting randomized, double-blind, placebo-controlled human clinical trials for dietary supplements and botanical new drug candidates (NDAs). Delivering GCP-audited clinical study reports (CSR) for seamless submission to international regulators.
Addressing the practical operational hurdles faced by functional food producers, ethical botanical pharmaceuticals, and clinical institutions worldwide.
Natural polyphenols and terpenes often exhibit suboptimal gastrointestinal absorption and rapid phase II metabolic clearance. Our ODM platform engineers microencapsulated systems, liposomal dispersion matrices, and self-emulsifying delivery systems (SEDDS) to achieve superior human clinical bioavailability without chemical excipients.
Hospital in-house formulations possess immense clinical value but lack transferrable industrial quality parameters. MedGence has successfully obtained 56 hospital preparation registrations by converting traditional decoction parameters into high-precision, pilot-scale fluid extracts and spray-dried granulates that preserve the original herbal matrix.
Plant-derived cosmeceuticals require documented proof of non-irritation alongside clear mechanistic action. We deliver complete cutaneous absorption models, in vitro human keratinocyte (HaCaT) assays, collagenase/elastase inhibition profiles, and repeated patch testing for premium global skincare brands.
Our long-term contract research relationships reflect unwavering adherence to scientific precision, data confidentiality, and cGMP compliance.
In-depth insights into study architecture, analytical validation, regulatory compliance, and proprietary asset protection.
Advance your botanical development program with fully validated preclinical dossiers, standardized raw materials, and finished formulations.
